TEVA Teva Pharmaceutical Industries Ltd

Additionally, on June 7, 2023 the Company reached a settlement to resolve all opioid-related claims brought by the state of Nevada and its litigating subdivisions and special districts. Trial in the state’s case had been scheduled to begin in August 2023. Under the terms of the settlement with Nevada, Teva will pay Nevada $193 million over 20 years (including all fees and costs).

The Company issued a press release on June 8, 2023 to announce that it has fully resolved its Nationwide Opioids Settlement Agreement and to announce its separate settlement with the state of Nevada. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. As of the date of this Current Report on Form 8-K, the Company has settled opioid claims brought by all 50 U.S. states and more than 99% of the litigating subdivisions and special districts within those states.

The information in this Item 7.01 and Exhibit 99.1 hereto is being furnished to the Securities and Exchange Commission (the “Commission”) and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act or the Exchange Act, except as set forth by specific reference in such filing.

Cautionary Statements Regarding Forward-Looking Statements

The foregoing description of the Nationwide Opioids Settlement Agreement and the expected resolution of the opioids-related claims brought against the Company by various state and political subdivisions contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. You can identify these forward-looking statements by the use of words such as “should,” “expect,” “anticipate,” “estimate,” “target,” “may,” “project,” “guidance,” “intend,” “plan,” “believe” and other words and terms of similar meaning and expression. The reader should not place undue reliance on forward-looking statements, which speak only as of the date they are first made. Except to the extent required by law, the Company undertakes no obligation to publicly update forward-looking statements. Risk factors include, but are not limited to: the Nationwide Opioids Settlement Agreement is not expected to result in a resolution of all governmental entity claims against the Company regarding its role in distributing opioids; the Company expects to continue to experience costly and disruptive legal disputes and settlements related to distribution of controlled substances, including opioids; and the settlement payments that the Company is required to make under the Nationwide Opioids Settlement Agreement may have an adverse impact on the Company’s operations and cash flows and there is no assurance that the Company will have the liquidity or other resources necessary to make such payments and provide supplies of its generic version of Narcan^® (naloxone hydrochloride nasal spray) in the amounts and at the times required under the terms of the Nationwide Opioids Settlement Agreement. Investors should read the important risk factors described in the Company’s most recent Annual Report on Form 10-K, Quarterly Report on Form 10-Q and Current Reports on Form 8-K filed with the Commission.